Palisade Bio, Inc. (NASDAQ:PALI) Short Interest Update

Palisade Bio, Inc. (NASDAQ:PALI) was the recipient of a large increase in short interest in March. As of March 15th, there was short interest totalling 291,500 shares, an increase of 97.0% from the February 28th total of 148,000 shares. Based on an average trading volume of 566,700 shares, the days-to-cover ratio is currently 0.5 days. Approximately 10.6% of the company’s stock are short sold.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Palisade Bio stock. JPMorgan Chase & Co. bought a new stake in Palisade Bio, Inc. (NASDAQ:PALI) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 8,200 shares of the company’s stock, valued at approximately $29,000. JPMorgan Chase & Co. owned 0.54% of Palisade Bio at the end of the most recent reporting period. 11.79% of the stock is currently owned by institutional investors and hedge funds.

Palisade Bio Stock Performance

NASDAQ:PALI traded up $0.01 during midday trading on Friday, reaching $0.70. 25,056 shares of the stock traded hands, compared to its average volume of 761,427. The stock has a market capitalization of $1.94 million, a PE ratio of -0.05 and a beta of 1.49. Palisade Bio has a 12-month low of $0.65 and a 12-month high of $9.65. The business has a 50-day moving average of $1.04 and a two-hundred day moving average of $2.11.

Palisade Bio (NASDAQ:PALI) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.69) EPS for the quarter, beating analysts’ consensus estimates of ($2.39) by $1.70. Research analysts anticipate that Palisade Bio will post -12.43 earnings per share for the current year.

About Palisade Bio

Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage.